Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157558 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02157558 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT02157558, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.
Interventions
- DRUG Fexofenadine
- DRUG Telotristat etiprate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157558
The ClinicalTrials.gov registry entry for NCT02157558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fexofenadine is the first listed.
NCT02157558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157558 about?
NCT02157558 is a clinical study titled "An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects". The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.
What is the current status of trial NCT02157558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-07.
What interventions are being tested in trial NCT02157558?
The interventions under investigation include: Fexofenadine (DRUG), Telotristat etiprate (DRUG).
Who is sponsoring clinical trial NCT02157558?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.